Publications by authors named "Kazuyoshi Minemura"
Aims: To examine the safety and efficacy of vibegron, a new β3-adrenoceptor agonist, in patients aged ≥65 years, with a focus on the effects on cardiovascular system and overactive bladder (OAB) symptoms.
Methods: A post-hoc subgroup analysis was performed of a randomized, placebo-controlled, double-blind comparative phase 3 study of vibegron, including those assigned to receive either vibegron 50 mg (V50), vibegron 100 mg (V100), or placebo for 12 weeks. Subjects were stratified into two subgroups based on age: a <65-year subgroup and a ≥65-year subgroup.
Article Synopsis
- The study evaluated the effectiveness of vibegron, a β3-adrenoreceptor agonist, for treating urgency urinary incontinence (UUI) in patients with overactive bladder (OAB).
- It analyzed data from a phase 3 trial comparing vibegron to a placebo, categorizing patients based on the severity of their UUI.
- Results showed that vibegron significantly reduced UUI episodes and increased the percentage of patients achieving 'diary-dry' status compared to placebo, particularly in both mild/moderate and severe UUI subgroups.
Objectives: To investigate the efficacy of vibegron on nocturia in patients with overactive bladder.
Methods: Among the Japanese overactive bladder patients enrolled in the placebo-controlled, multicenter, randomized, double-blind phase 3 study of vibegron, a total of 669 patients with nocturia (≥1 nocturnal void) were included. Changes from baseline in micturition parameters were compared for vibegron treatment (50 and 100 mg/day) versus placebo.